Although ovarian cancer is not a common type of cancer observed in women, it is one of the dreadful cancers with high mortality rates. It requires an early diagnosis and proper treatment follow-up of the patients. In early suspicion and diagnosis of ovarian cancer the general practitioners or the primary care doctors can play a major role. Detecting ovarian cancer at primary care is highly challenging due to the nonspecific symptoms. Based on the guidelines published by the National Institute for Health and Clinical Excellence (NICE) performing CA125 test could be useful in detecting ovarian cancer or ovarian cysts. As postmenopausal women with ovarian cysts or cancer is expected to have a different level of serum CA125 compared to the threshold level of 35 IU/ml. Moreover, performing ultrasound scans as a tool of first line investigation can provide better results in diagnosing ovarian cancer among women. Adhering to the NICE guidelines the general practitioners can suspect and diagnose ovarian cancer.
1. If a woman (especially if 50 or over) reports having any of the symptoms like abdominal distention, feeling full or loss of appetite, abdominal pain, increased urinary frequency persisting or having on a frequent basis, particularly more than 12 times per month, the individual can be suspected of having ovarian cancer
2. Women aging >50 years had a threefold incidence of ovarian cancer compared to others
3. Women with abnormal CA125 test results (>35 U/mL), 15.2 percent of those aged ≥50 years and 3.4 percent of those aged <50 years are expected to have ovarian cancer.
4. The probability of ovarian cancer is 3 percent in women with a CA125 level of 51 U/mL and it is recommended for urgent cancer referral by NICE.
CA125:
The CA125 test can be highly useful in detecting ovarian cancer in general practice but it can detect non ovarian cancers as well which include chest, abdomen, and pelvis. An elevation of 49, 47 and 36 percent in the levels of CA125 observed in women diagnosed with pancreatic, lung, and uterine cancer, respectively and thus the GP’s need to have the knowledge of these as well. Therefore, while managing a symptomatic woman who has elevated CA125 levels clinicians need to consider performing appropriate investigations for other cancers also in order to avoid diagnostic delay. The tumor marker CA125 may also lack sensitivity which can lead to false results, therefore, the physicians should also consider other imaging techniques in order to confirm the suspect of ovary cancer among women and further research in this area also needs to be initiated in order to get a more clear picture for the use of CA125.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
2.
Formaldehyde releasers found in common personal care products used especially by Black and Latina women
3.
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer
4.
'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link
5.
GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.
1.
Biomimetic Nanovesicles Target Senescent-Escape Cancer Stem Cells in Breast Cancer
2.
Exploring the Mysteries of Myxoma: A New Frontier in Medical Research
3.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
4.
Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide
5.
Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
2.
Navigating the Complexities of Ph Negative ALL - Part X
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation